MARKET

GUTS

GUTS

Fractyl Health
NASDAQ
0.7512
-0.0035
-0.46%
Opening 15:53 05/11 EDT
OPEN
0.7742
PREV CLOSE
0.7547
HIGH
0.8200
LOW
0.7467
VOLUME
2.99M
TURNOVER
--
52 WEEK HIGH
3.030
52 WEEK LOW
0.3772
MARKET CAP
119.18M
P/E (TTM)
-0.4041
1D
5D
1M
3M
1Y
5Y
1D
Analysts Have Conflicting Sentiments on These Healthcare Companies: Apellis Pharmaceuticals (APLS), Fractyl Health, Inc. (GUTS) and Inhibrx Biosciences Inc (INBX)
TipRanks · 7h ago
Fractyl Health Advances RJVA-001 Gene Therapy Trial
TipRanks · 9h ago
Fractyl Health Receives Clinical Trial Application Authorization In Netherlands To Initiate Phase 1/2 First-in-human Study Of RJVA-001, Expects To Start Dosing And Report Preliminary Data In 2H of 2026
Benzinga · 10h ago
Fractyl Health wins Dutch clearance to start RJVA-001 first-in-human trial
PUBT · 10h ago
FRACTYL HEALTH INC - REJUVA CLINICAL DEVELOPMENT FUNDED INTO EARLY 2027 WITH NO CHANGE TO CAPITAL PLANS
Reuters · 10h ago
Weekly Report: what happened at GUTS last week (0504-0508)?
Weekly Report · 12h ago
Fractyl Health updates financial calendar ahead of quarterly results webcast
PUBT · 6d ago
Weekly Report: what happened at GUTS last week (0427-0501)?
Weekly Report · 05/04 09:19
More
About GUTS
Fractyl Health, Inc. is a metabolic therapeutics company. The Company is focused on developing new approaches to the treatment of metabolic diseases, including obesity and type 2 diabetes (T2D). The Company’s lead product candidate, Revita, is designed to remodel the duodenal lining via hydrothermal ablation (i.e. duodenal mucosal resurfacing) to reverse damage to intestinal nutrient sensing and signaling mechanisms caused by chronic high-fat and high-sugar diets that are a root cause of metabolic disease. The Revita clinical program is focused on patients living with obesity who want to maintain their weight loss after GLP-1 drug discontinuation. The Company’s Rejuva platform focuses on developing adeno-associated virus (AAV)-based, locally delivered gene therapies for the treatment of obesity and T2D. The Rejuva platform leverages advanced delivery systems and proprietary screening methods to identify and develop metabolically active gene therapy candidates targeting the pancreas.

Webull offers Fractyl Health Inc stock information, including NASDAQ: GUTS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GUTS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GUTS stock methods without spending real money on the virtual paper trading platform.